Skip to content

Mepivacaine Versus Bupivacaine Onset Time in Ultrasound-guided Ankle Blocks

Onset of Sensory Blockade in Ultrasound-Guided Ankle Block With Mepivacaine Versus Bupivacaine: A Randomized Non-Inferiority Clinical Trial

Status
Enrolling by invitation
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05425979
Enrollment
50
Registered
2022-06-21
Start date
2024-03-11
Completion date
2027-03-30
Last updated
2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle Block, Foot Surgery

Keywords

Ultrasound-Guided Ankle Block, Regional anesthesia, Local anesthesia

Brief summary

The purpose of this research is to determine if both local anesthetics (mepivacaine and bupivacaine) are similar in their onset of sensory block to assess the efficiency of ultrasound-guided ankle blocks in our practice. Currently it is the standard of care to perform ankles blocks with both mepivacaine and bupivacaine. However, given similarity in their safety profile researchers would like to compare if one is non-inferior to the other in terms of onset time of ankle block.

Interventions

DRUGMepivacaine

Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves

DRUGBupivacaine

Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Participants, the anesthesiologist performing the block and assessing the block efficacy over time will all be masked as to which local anesthetic is being used

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than or equal to 18 years old. * Patients who provide informed consent to participate. * Patients undergoing foot surgery who require a peripheral nerve block of the ankle as primary anesthesia. * ASA (American Society of Anesthesiology) Physical Status Classification I - III.

Exclusion criteria

* Inability to consent. * Allergy to local anesthetic. * Infection at site of injection. * Pregnancy. * Coagulopathy. * Hepatic or renal failure. * Preexisting neuropathy in operative limb. * Planned spinal anesthetic or general anesthesia.

Design outcomes

Primary

MeasureTime frameDescription
Onset of sensory Blockage20 minutesTime in minutes for successful surgical sensory blockade following the ankle block

Secondary

MeasureTime frameDescription
Pain ScoresPost-procedural, approximately 2-4 hoursPain scores in post-anesthesia care unit (PACU) will be obtained using the numerical rating scale (0-10 point scale with 0 representing no pain and 10 representing the worst possible pain)
Total opioid received intra-operativelyIntra-operatively, approximately 4-6 hoursTotal amount of opioid received intra-operatively
Time to first opioid use24 hoursTime measured in minutes to the first opioid use
Number of complications24 hourTotal number of procedural complications
Block Failure20 minutesNumber of subjects to experience block failure as defined as opioid administration operatively and /or conversion to general anesthesia
Overall Benefit of Analgesia Score (OBAS)24 hours after dischargeSeven questions to access pain intensity, adverse effects and satisfaction with treatment. Possible score range from 0 to 24, with higher scores indicating worse outcome
Total opioid use after discharge24 hours after dischargeTotal amount of opioids used used for pain control after discharge
Duration of the ankle block24 hours after dischargeLength of time measured in minutes the patient to felt until the ankle block completely wore off
Total anesthesia-related time20 minutesMeasured in minutes, defined as performance time plus onset time of local anesthesia

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026